Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) RIFADINE rifampicin 150mg capsules (Belgium)
Section 19A approved medicine
(Approval lapsed) RIFADINE rifampicin 150mg capsules (Belgium)
Section 19A approval holder
Sanofi Aventis Australia Pty Ltd ABN 31 008 55 8807
Phone
1800 818 806
Approved until
Status
Expired
Medicines in short supply/unavailable
RIMYCIN 150 rifampicin 150 mg capsule bottle - ARTG 48230
Indication(s)
Tuberculosis
In the initial treatment and in retreatment of patients with tuberculosis, Rifadin must be used in conjunction with at least one other antituberculosis drug.
Leprosy
In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. As an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs.
As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs.
Meningococcal Disease Prophylaxis of meningococcal disease in close contacts of known cases and in carriers (Rifadin is not indicated for the treatment of meningococcal infections).
Haemophilus Influenzae
Prophylaxis of household contacts of patients with H. influenzae type B.
Images
